Literature DB >> 25949887

Tumor immune remodeling by TGFβ inhibition improves the efficacy of radiation therapy.

Kristina H Young1, Michael J Gough2, Marka Crittenden3.   

Abstract

The tumor immune environment has been linked to prognosis in patients with a range of malignancies. Recently, we demonstrated in pre-clinical models that modifying the tumor immune environment using a small-molecule inhibitor of TGFb significantly improved outcome to subsequent radiation therapy. These data suggest that this and other immunotherapies may be used to remodel the tumor before conventional cancer therapies to improve outcomes.

Entities:  

Keywords:  TGFβ; colorectal; immunoscore; immunotherapy; pancreas; radiation

Year:  2014        PMID： 25949887      PMCID： PMC4404800          DOI： 10.4161/21624011.2014.955696

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN： 2162-4011            Impact factor:   8.110


  10 in total

1.  Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy.

Authors:  David G DeNardo; Donal J Brennan; Elton Rexhepaj; Brian Ruffell; Stephen L Shiao; Stephen F Madden; William M Gallagher; Nikhil Wadhwani; Scott D Keil; Sharfaa A Junaid; Hope S Rugo; E Shelley Hwang; Karin Jirström; Brian L West; Lisa M Coussens
Journal:  Cancer Discov       Date:  2011-06-01       Impact factor: 39.397

2.  Immune-mediated eradication of tumors through the blockade of transforming growth factor-beta signaling in T cells.

Authors:  L Gorelik; R A Flavell
Journal:  Nat Med       Date:  2001-10       Impact factor: 53.440

3.  TGFβ inhibition prior to hypofractionated radiation enhances efficacy in preclinical models.

Authors:  Kristina H Young; Pippa Newell; Benjamin Cottam; David Friedman; Talicia Savage; Jason R Baird; Emmanuel Akporiaye; Michael J Gough; Marka Crittenden
Journal:  Cancer Immunol Res       Date:  2014-07-21       Impact factor: 11.151

4.  LY2109761 attenuates radiation-induced pulmonary murine fibrosis via reversal of TGF-β and BMP-associated proinflammatory and proangiogenic signals.

Authors:  Paul Flechsig; Monika Dadrich; Sebastian Bickelhaupt; Jürgen Jenne; Kai Hauser; Carmen Timke; Peter Peschke; Eric W Hahn; Hermann-Josef Gröne; Jonathan Yingling; Michael Lahn; Ute Wirkner; Peter E Huber
Journal:  Clin Cancer Res       Date:  2012-04-30       Impact factor: 12.531

5.  The small molecule TGF-β signaling inhibitor SM16 synergizes with agonistic OX40 antibody to suppress established mammary tumors and reduce spontaneous metastasis.

Authors:  Kendra Garrison; Tobias Hahn; Wen-Cherng Lee; Leona E Ling; Andrew D Weinberg; Emmanuel T Akporiaye
Journal:  Cancer Immunol Immunother       Date:  2011-10-05       Impact factor: 6.968

6.  Type, density, and location of immune cells within human colorectal tumors predict clinical outcome.

Authors:  Jérôme Galon; Anne Costes; Fatima Sanchez-Cabo; Amos Kirilovsky; Bernhard Mlecnik; Christine Lagorce-Pagès; Marie Tosolini; Matthieu Camus; Anne Berger; Philippe Wind; Franck Zinzindohoué; Patrick Bruneval; Paul-Henri Cugnenc; Zlatko Trajanoski; Wolf-Herman Fridman; Franck Pagès
Journal:  Science       Date:  2006-09-29       Impact factor: 47.728

7.  TGFβ1 inhibition increases the radiosensitivity of breast cancer cells in vitro and promotes tumor control by radiation in vivo.

Authors:  Fanny Bouquet; Anupama Pal; Karsten A Pilones; Sandra Demaria; Byron Hann; Rosemary J Akhurst; Jim S Babb; Scott M Lonning; J Keith DeWyngaert; Silvia C Formenti; Mary Helen Barcellos-Hoff
Journal:  Clin Cancer Res       Date:  2011-10-25       Impact factor: 12.531

8.  Inhibition of transforming growth factor-beta, hypoxia-inducible factor-1alpha and vascular endothelial growth factor reduced late rectal injury induced by irradiation.

Authors:  Yong Liu; Kohsei Kudo; Yoshinao Abe; Dong-Liang Hu; Hiroshi Kijima; Akio Nakane; Koji Ono
Journal:  J Radiat Res       Date:  2009-04-04       Impact factor: 2.724

9.  An orally active small molecule TGF-beta receptor I antagonist inhibits the growth of metastatic murine breast cancer.

Authors:  Matthew P Rausch; Tobias Hahn; Lalitha Ramanathapuram; Deborah Bradley-Dunlop; Daruka Mahadevan; Melania E Mercado-Pimentel; Raymond B Runyan; David G Besselsen; Xiamei Zhang; H-Kam Cheung; Wen-Cherng Lee; Leona E Ling; Emmanuel T Akporiaye
Journal:  Anticancer Res       Date:  2009-06       Impact factor: 2.480

Review 10.  The impact of the myeloid response to radiation therapy.

Authors:  Michael J Gough; Kristina Young; Marka Crittenden
Journal:  Clin Dev Immunol       Date:  2013-04-07
  10 in total
  3 in total

Review 1.  Trial Watch: Immunotherapy plus radiation therapy for oncological indications.

Authors:  Erika Vacchelli; Norma Bloy; Fernando Aranda; Aitziber Buqué; Isabelle Cremer; Sandra Demaria; Alexander Eggermont; Silvia Chiara Formenti; Wolf Hervé Fridman; Jitka Fucikova; Jérôme Galon; Radek Spisek; Eric Tartour; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2016-07-25       Impact factor: 8.110

2.  Lung cancer deficient in the tumor suppressor GATA4 is sensitive to TGFBR1 inhibition.

Authors:  Lei Gao; Yong Hu; Yahui Tian; Zhenzhen Fan; Kun Wang; Hongdan Li; Qian Zhou; Guandi Zeng; Xin Hu; Lei Yu; Shiyu Zhou; Xinyuan Tong; Hsinyi Huang; Haiquan Chen; Qingsong Liu; Wanting Liu; Gong Zhang; Musheng Zeng; Guangbiao Zhou; Qingyu He; Hongbin Ji; Liang Chen
Journal:  Nat Commun       Date:  2019-04-10       Impact factor: 14.919

Review 3.  Development and therapeutic manipulation of the head and neck cancer tumor environment to improve clinical outcomes.

Authors:  Thomas Duhen; Michael J Gough; Rom S Leidner; Sasha E Stanton
Journal:  Front Oral Health       Date:  2022-07-22
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.